Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Open Access
- 20 July 2023
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 37 (8) , 671-677
Abstract
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Numerous biomarker studies have clearly demonstrated that AD has a long asymptomatic phase, with the development of pathology occurring at least 2 decades prior to the development of any symptoms. These pathological changes include a stepwise development of amyloid-β (Aβ) plaques, followed by tau neurofibrillary tangles and subsequently extensive neurodegeneration in the brain. In this review, we discuss the first class of drugs intended to be disease modifying to be approved by the US Food and Drug Administration (FDA) for AD—anti-Aβ monoclonal antibodies—and the scientific rationale with which they were developed.Keywords
Funding Information
- National Institute on Aging (1U24AG057437)
- University of Southern California
This publication has 28 references indexed in Scilit:
- Amyloid beta: structure, biology and structure-based therapeutic developmentActa Pharmacologica Sinica, 2017
- Plaque formation and the intraneuronal accumulation of β‐amyloid in Alzheimer's diseasePathology International, 2017
- The Role of Amyloid-β Oligomers in Toxicity, Propagation, and ImmunotherapyEBioMedicine, 2016
- Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's diseaseNeuropeptides, 2015
- Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s diseaseFrontiers in Cellular Neuroscience, 2015
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersThe Lancet Neurology, 2013
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable WorkgroupAlzheimer's & Dementia, 2011
- Incidence of cerebral microbleedsNeurology, 2010
- Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicityProceedings of the National Academy of Sciences, 2010
- The Genetics of Alzheimer DiseaseArchives of Neurology, 1998